Published in Health Risk Factor Week, July 24th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at GlaxoSmithKline.
Report 1: GlaxoSmithKline plc (LSE and NYSE: GSK) announced long-term efficacy data from a Phase II trial of a single one-week course of frontline treatment with the BEXXAR(R) Therapeutic Regimen (Tositumomab and Iodine I-131 Tositumomab) in 76 patients with newly diagnosed advanced follicular non-Hodgkin's lymphoma (NHL). This regimen was found to induce durable clinical and molecular remissions in patients with this disease. Specifically, researchers reported that patients who...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Risk Factor Week